- Report
- August 2025
- 187 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 184 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- June 2025
- 130 Pages
Global
From €3639EUR$4,123USD£3,148GBP
€4281EUR$4,850USD£3,703GBP
- Report
- May 2025
- 100 Pages
Global
From €4325EUR$4,900USD£3,742GBP
- Report
- March 2025
- 200 Pages
Global
From €2198EUR$2,490USD£1,901GBP
- Report
- August 2025
- 181 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 181 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 188 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 185 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 197 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 199 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 197 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 199 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 193 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- August 2025
- 188 Pages
Global
From €3129EUR$3,545USD£2,707GBP
€3477EUR$3,939USD£3,008GBP
- Report
- April 2025
- 175 Pages
Global
From €3963EUR$4,490USD£3,429GBP
- Report
- April 2025
- 175 Pages
Global
From €3963EUR$4,490USD£3,429GBP
- Report
- April 2025
- 175 Pages
Global
From €3963EUR$4,490USD£3,429GBP
- Report
- April 2025
- 175 Pages
Global
From €3963EUR$4,490USD£3,429GBP
- Report
- March 2025
- 200 Pages
Global
From €3963EUR$4,490USD£3,429GBP

Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the naturally occurring enzyme plasminogen.
The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more